Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
Source: washingtontimes.com
Please follow and like us:
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition
Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
Source: washingtontimes.com